Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IONS
IONS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IONS News
Bepirovirsen Shows Significant Efficacy in Chronic Hepatitis B Trials
2d ago
Newsfilter
GSK's Antisense Drug Shows Promise in Hepatitis B Trials
2d ago
seekingalpha
Citi Initiates Bullish Coverage on SMid Cap Biotechs
May 19 2026
seekingalpha
Biogen's Alzheimer Therapy Trial Shows Promising Results
May 14 2026
seekingalpha
Ionis Pharmaceuticals (IONS.US) Director Plans to Sell $4.35 Million in Common Stock via Form 144
May 05 2026
moomoo
Ionis Pharmaceuticals to Participate in Multiple Investor Conferences
May 01 2026
Newsfilter
Ionis Pharmaceuticals Q1 2026 Earnings Call Highlights
Apr 29 2026
seekingalpha
Ionis (IONS) Q1 2026 Earnings Call Transcript
Apr 29 2026
NASDAQ.COM
Ionis Pharmaceuticals Q1 Earnings Beat Expectations with 86.4% Revenue Growth
Apr 29 2026
seekingalpha
Ionis Pharmaceuticals Q1 Earnings Announcement Scheduled
Apr 28 2026
seekingalpha
GSK Receives FDA Priority Review for Hepatitis B Therapy
Apr 28 2026
seekingalpha
FDA Accepts Priority Review for Bepirovirsen by GSK and Ionis
Apr 28 2026
NASDAQ.COM
Ionis and GSK's New Drug Application Receives FDA Priority Review
Apr 28 2026
Newsfilter
IONIS PHARMACEUTICALS INC - FDA Establishes PDUFA Deadline for Bepirovirsen on October 26, 2026
Apr 28 2026
moomoo
GSK, IONIS PARTNER, ANNOUNCES BEPIROVIRSEN RECEIVES PRIORITY REVIEW AND BREAKTHROUGH THERAPY DESIGNATION FROM U.S. FDA AS A POTENTIAL FIRST-IN-CLASS TREATMENT FOR CHRONIC HEPATITIS B
Apr 28 2026
moomoo
Pharma Giants Race to Develop Heart Attack Prevention Drugs
Apr 27 2026
CNBC
Show More News
